Become A Featured Company

Abattis Bioceuticals Offers “Comfort” to Those Suffering with Chronic Pain & Inflammation

Ryan Allway

October 30th, 2018

Exclusive, News, Top Story

Abattis Bioceuticals Corp. (CSE: ATT) (OTC: ATTBF) latest innovation is “Comfort”, a nutraceutical designed to alleviate chronic pain and inflammation – the first in line of a dozen new products the company expects to launch over 36 months.

According to a recent Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, stated “acute or chronic pain is a significant public health problem that costs society at least $560-$635 billion annually in North America alone. This includes the total incremental cost of healthcare in North America due to pain ranging between $261 to $300 billion and $297-$336 billion due to lost productivity (based on days of work missed, hours of work lost, and lower wages). Additionally, the number of deaths associated with nonsteroidal anti-inflammatory drugs and opioids commonly used to treat those with chronic pain and inflammation has risen steadily.”

Overall, much more needs to be done to meet the challenges of pain and increase the widespread awareness of it. Abattis Bioceuticals took this goal to heart and set to work, analyzing not only the symptoms, but the physiology behind acute and chronic pain. The result is Comfort.

Activating Cannabinoid Receptors

According to Dr. Brazos Minshew, MSc, ND and President of the Abattis Medical Advisory Board, chronic pain occurs when internal systems within the body break down and fail to produce important chemicals necessary for regulating pain. This is because when our bodies experience severe, sustained pain, the ability to produce the endocannabinoids and endorphins which reduce our perception of pain slows and eventually stops altogether, resulting in the condition commonly referred to as chronic pain.

One of the body’s key pain management systems works through the production of bioactive lipids known as endocannabinoids which bind to and activate the CB-1 and CB-2, our body’s main cannabinoid receptors. When activated, the CB-1 and CB-2 modulate neural activity, helping our bodies cope with pain without becoming overwhelmed.

Comfort, Abattis’ proprietary nutraceutical – a pharmaceutical-grade, standardized nutrient – naturally stimulates the endocannabinoid system and the production of endorphins using ingredients such as Alpinia Galangal, a rare phytocannabinoid from the Ginger family, typically found in Indonesia and Malaysia, as well as Capsicum Annuum, which derives from the Pepper family, both of which have long been regarded for their medicinal properties. Alpinia Galangal  in particular, has been historically used to treat a range of ailments including gastrointestinal distress, and more recently, it’s been used to improve mental alertness, as an ingredient in cancer treatments, to reduce pain and inflammation, in addition to improving mobility. The company has secured a consistent supply of the ingredients on which Comfort is based.

Abattis plans to launch Comfort on Cyber Monday (November 26th, 2018) through its wholly-owned natural product management subsidiary – Vergence Naturals. Vergence is already regarded as a leader in the supply, sourcing, and promotion of naturally-inspired health and beauty brands for the conventional and cannabinoid-enhanced markets. The marketing campaign for Comfort will draw public attention to the benefits of phytocannabinoids, especially in pain management.

Arriving in just over a month after the full legalization of cannabis across the country, this will be the first Cyber Monday in which Canadians will be able to legally purchase products containing THC and/or CBD online, so it’s likely this Cyber Monday will once again set records.

Beyond Comfort

The release of Comfort will round out a busy year for Abattis Bioceuticals, which has advanced an ambitious business plan focused well beyond flower production and cultivation to the in-house research, development, marketing, and distribution of high-margin, high-growth cannabis-derived products.

Along with the construction of a 26,000 square foot production & extraction facility in British Columbia for its wholly-owned subsidiary, Gabriola Green Farms. Abattis has also partnered with XLABS Therapeutics to open a new 10,000 square foot cannabis laboratory in Belleville, Ontario (with an additional 310,000 square feet available for future expansion) to service the growing cannabis sector. The new production facility will allow Abattis to control its own raw material production. This is important from a financial perspective, product development perspective and quality control standpoint. The lab will give the company a strong presence on Canada’s East Coast and allow it to pursue medicinal cannabis research while offering lab services to third-parties.

Abattis is working with Northern Vine Labs to carry out R&D and analytical testing on a hemp-infused, cannabinoid-rich, THC-free craft beer in conjunction with Faculty Brewing Company. The micro-brewery is developing a variety of cannabis-based beverages in partnership with other companies. It has already developed a prototype CBD-infused sunscreen and continues work on the development of nano-emulsified and liposomal platforms for the delivery of a cannabinoid-rich hemp oil in collaboration with the University of British Columbia.

The legalization of cannabis in Canada is expected to see consumers moving away from smoking flower and toward vaping, sublinguals, creams, and oils – as other regions have experienced following legalization. Abattis is well-placed to provide a variety of alternatives, through its wholly-owned subsidiary – Green Tree Therapeutics.

The company has introduced three industry-benchmarked, Abattis branded vaporizers, and as a result will be able to load the line with its own cannabinoid formulations and retail them directly through its diverse distribution channels. Abattis vaporizers feature a 510-thread battery that can be used with any third-party cartridge.

Many of these product areas are still in their infancy, but with legalization here, cannabis research will become more efficient and cost-effective, paving the way for even greater innovation.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading